Post hoc analysis finds tirzepatide cuts sleep apnea severity across patient subgroups
The reanalysis looks at obstructive sleep apnea, long managed first with continuous positive airway pressure machines rather than drug therapy.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 22 16:23 ETSource: Bioengineer.org
The wire
- 01A post hoc analysis of tirzepatide trial data reports reductions in obstructive sleep apnea severity that held consistently across the patient types examined.
- 02Clinicians treating obesity-related sleep apnea have a pharmacologic option to weigh alongside CPAP, and payers increasingly ask for subgroup evidence.
- 03Post hoc subgroup analyses are exploratory and not powered to prove benefit in any one group; the underlying trial design still drives interpretation.
From the source
Read at bioengineer.orgTirzepatide Eases Sleep Apnea Across All Patient Types, Landmark Post Hoc Analysis Shows
Obstructive sleep apnea, a disorder in which the upper airway repeatedly collapses during sleep, affects hundreds of millions of people worldwide and quietly drives up the risk of cardiovascular disease, metabolic dysfunction, and daytime exhaustion. For decades, the first-line treatment has been a machine: continuous
